• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

    9/3/24 7:10:06 PM ET
    $BFLY
    Medical Electronics
    Health Care
    Get the next $BFLY alert in real time by email
    SC 13D/A 1 ef20035391_sc13da.htm SC 13D/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

    SCHEDULE 13D
    (Rule 13d-101)

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)*

    BUTTERFLY NETWORK, INC.
    (Name of Issuer)

    Common Stock, par value $0.0001
    (Title of Class of Securities)

    124155102
    (CUSIP Number)

    Mark Horowitz
    Co-President
    Glenview Capital Management, LLC
    767 Fifth Avenue, 44th Floor
    New York, NY 10153
    (212) 812-4700
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    August 29, 2024
    (Date of Event Which Requires Filing of This Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 124155102
     
    Page 2 of 7 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    GLENVIEW CAPITAL MANAGEMENT, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    AF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    11,668,477 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    11,668,477 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    11,668,477 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    6.21% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)
    Includes (i) 9,955,144 shares of Common Stock held directly by Glenview Capital Management, LLC and (ii) 1,713,333 shares of Common Stock issuable to Glenview Capital Management, LLC upon exercise of the Private Placement Warrants.
    (2)
    Based on 186,147,353 shares of Common Stock outstanding as of July 18, 2024, as reported in the Issuer’s Form 10-Q filed on August 1, 2024, plus the shares of Common Stock the Reporting Person has the right to acquire, which shares have been added to the total shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.


    CUSIP No. 124155102
     
    Page 3 of 7 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    LARRY ROBBINS
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    AF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    UNITED STATES OF AMERICA
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    306,716 (3)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    19,247,764 (4)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    306,716 (3)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    19,247,764 (4)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    19,554,480 (3)(4)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    10.23% (5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN, HC
     
     
     
     

    (3)
    Includes (i) 21,645 shares of Common Stock that Mr. Robbins has the right to acquire upon exercise of stock options and (ii) 157,894 shares of Common Stock underlying unvested restricted stock units that were granted to Mr. Robbins, which vest in full on the date of the Issuer's 2025 Annual Stockholders Meeting, subject to Mr. Robbins’ continued service on the Issuer’s board of directors on such date.
    (4)
    Includes (i) 9,955,144 shares of Common Stock held directly by Glenview Capital Management, LLC, (ii) 4,546,687 shares of Common Stock held directly by Longview Investors LLC, (iii) 3,032,600 shares of Common Stock issuable to Longview Investors LLC upon exercise of the Private Placement Warrants and (iv) 1,713,333 shares of Common Stock issuable to Glenview Capital Management, LLC upon exercise of the Private Placement Warrants.
    (5)
    Based on 186,147,353 shares of Common Stock outstanding as of July 18, 2024, as reported in the Issuer’s Form 10-Q filed on August 1, 2024, plus the shares of Common Stock the Reporting Person has the right to acquire, which shares have been added to the total shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.


    CUSIP No. 124155102
     
    Page 4 of 7 Pages
    SCHEDULE 13D

    Item 1.
    Security and Issuer.

    Item 1 of the Schedule 13D is hereby amended and supplemented as follows.

    This Amendment No. 4 (“Amendment No. 4”) amends and supplements the information set forth in the Schedule 13D filed by the Reporting Persons (as defined herein) and Longview Investors LLC (“Longview”) with the U.S. Securities and Exchange Commission (the “SEC”) on February 17, 2021, as amended by Amendment No. 1, filed with the SEC on March 30, 2021, Amendment No. 2, filed with the SEC on March 11, 2022, and Amendment No. 3, filed with the SEC on February 14, 2023 (collectively, the “Schedule 13D”), relating to the Class A common stock, par value $0.0001 per share (the “Common Stock”), of Butterfly Network, Inc. (the “Issuer”). The Issuer’s principal executive offices are located at 1600 District Avenue, Burlington, MA 01803. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D. Except as specifically provided herein, this Amendment No. 4 does not modify any of the information previously reported in the Schedule 13D.

    Item 2.
    Identity and Background.

    Item 2 of the Schedule 13D is hereby amended and restated in its entirety as follows.

    (a) This Schedule 13D is filed on behalf of the following persons (collectively, the “Reporting Persons”):

     
    i)
    Glenview Capital Management, LLC (“Glenview”); and

     
    ii)
    Larry Robbins (“Mr. Robbins”).

    (b) The principal business address of each of the Reporting Persons is 767 Fifth Avenue, 44th Floor, New York, NY 10153.

    (c) This Schedule 13D relates to shares of Common Stock held by Longview and for the accounts of Glenview Capital Master Fund, Ltd., a Cayman Islands exempted company (“Glenview Capital Master Fund”), Glenview Offshore Opportunity Master Fund, Ltd., a Cayman Islands exempted company (“Glenview Offshore Opportunity Master Fund”), and Glenview Healthcare Master Fund, L.P., a Cayman Islands limited partnership (“Glenview Healthcare Master Fund” and collectively, the “Glenview Funds”). Glenview serves as investment manager to each of the Glenview Funds. Mr. Robbins is the Founder, Portfolio Manager and CEO of Glenview and the managing member of Longview. The present principal occupation of Mr. Robbins is Founder, Portfolio Manager and CEO of Glenview.

    (d) During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f) Glenview is a Delaware limited liability company. Mr. Robbins is a citizen of the United States of America.


    CUSIP No. 124155102
     
    Page 5 of 7 Pages
    Item 3.
    Source and Amount of Funds or Other Consideration.

    Item 3 of the Schedule 13D is hereby amended and supplemented as follows.

    Item 5(c) of this Amendment No. 4 is incorporated by reference herein. The funds used for the purchases of the shares of Common Stock reported in Item 5(c) of this Amendment No. 4 were derived from general working capital of the Glenview Funds. A total of approximately $1,950,797.41, including commissions, was paid to acquire the Shares purchased and reported in Item 5(c) of this Amendment No. 4.

    Item 5.
    Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is hereby amended and supplemented as follows:

    (a, b) Items 7-11 of the cover pages of the Schedule 13D are incorporated herein by reference.

    (c) Except for the transactions listed in Exhibit E of this Amendment No. 4, the Reporting Persons have not effected any transactions with respect to the Common Stock during the past 60 days.

    (d) The Glenview Funds are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported in this Schedule 13D as beneficially owned by Glenview (and indirectly beneficially owned by Mr. Robbins).

    (e) Not applicable.

    Item 7.
    Material to be Filed as Exhibits.

    Item 7 of the Schedule 13D is hereby amended and supplemented as follows:

    Exhibit E:  Schedule of Transactions for Item 5(c) of Amendment No. 4


    CUSIP No. 124155102
     
    Page 6 of 7 Pages
    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: September 3, 2024
     
       
     
    GLENVIEW CAPITAL MANAGEMENT, LLC
       
     
    By:
    /s/ Mark J. Horowitz
       
    Mark J. Horowitz
       
    Co-President of Glenview Capital Management, LLC
         
     
    LARRY ROBBINS
       
     
    By:
    /s/ Mark J. Horowitz
       
    Mark J. Horowitz, attorney-in-fact for Larry Robbins


    CUSIP No. 124155102
     
    Page 7 of 7 Pages
    EXHIBIT E
    SCHEDULE OF TRANSACTIONS

    Name of Account
    Title of Security
    Date of Transaction
    Nature of Transaction
    Type of Transaction
     
    Quantity
       Price
    Glenview Capital Master Fund
    Common Stock
    08/28/2024
    Purchase
    Private Transaction
       
    372,038(1)
     
    $0.9751
    Glenview Offshore Opportunity Master Fund
    Common Stock
    08/28/2024
    Purchase
    Private Transaction
       
    533,526(1)
     
    $0.9751
    Glenview Healthcare Master Fund
    Common Stock
    08/28/2024
    Purchase
    Private Transaction
       
    46,713(1)
     
    $0.9751
    Glenview Capital Master Fund
    Common Stock
    08/28/2024
    Purchase
    Open Market
       
    115,123
     
    $0.9937(2)
    Glenview Offshore Opportunity Master Fund
    Common Stock
    08/28/2024
    Purchase
    Open Market
       
    165,095
     
    $0.9937(2)
    Glenview Healthcare Master Fund
    Common Stock
    08/28/2024
    Purchase
    Open Market
       
    14,455
     
    $0.9937(2)
    Glenview Capital Master Fund
    Common Stock
    08/29/2024
    Purchase
    Open Market
       
    167,962
     
    $1.0746(3)
    Glenview Offshore Opportunity Master Fund
    Common Stock
    08/29/2024
    Purchase
    Open Market
       
    240,868
     
    $1.0746(3)
    Glenview Healthcare Master Fund
    Common Stock
    08/29/2024
    Purchase
    Open Market
       
    21,089
     
    $1.0746(3)
    Glenview Capital Master Fund
    Common Stock
    08/30/2024
    Purchase
    Open Market
       
    95,629
     
    $1.0714(4)
    Glenview Offshore Opportunity Master Fund
    Common Stock
    08/30/2024
    Purchase
    Open Market
       
    137,137
     
    $1.0714(4)
    Glenview Healthcare Master Fund
    Common Stock
    08/30/2024
    Purchase
    Open Market
       
    12,008
     
    $1.0714(4)

    (1) These shares were acquired directly from an affiliate of the Issuer in a private transaction.

    (2) This price reflects the weighted average price for open-market purchases of shares of Common Stock on August 28, 2024 within a $1.00 range. The actual prices for these transactions range from $0.952 to $1.00, inclusive. The Reporting Persons further undertake to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares of Common Stock purchased at each separate price.

    (3) This price reflects the weighted average price for open-market purchases of shares of Common Stock on August 29, 2024 within a $1.00 range. The actual prices for these transactions range from $1.01 to $1.10, inclusive. The Reporting Persons further undertake to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares of Common Stock purchased at each separate price.

    (4) This price reflects the weighted average price for open-market purchases of shares of Common Stock on August 30, 2024 within a $1.00 range. The actual prices for these transactions range from $1.035 to $1.09, inclusive. The Reporting Persons further undertake to provide upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares of Common Stock purchased at each separate price.



    Get the next $BFLY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFLY

    DatePrice TargetRatingAnalyst
    8/1/2025Outperform → Perform
    Oppenheimer
    7/1/2025$3.00Buy
    Craig Hallum
    3/17/2025Outperform
    William Blair
    9/10/2024$3.00Buy
    Lake Street
    3/29/2023$2.25Neutral
    UBS
    11/29/2022$4.50Outperform
    Oppenheimer
    10/4/2022$9.50Buy
    B. Riley Securities
    12/17/2021$7.00Neutral
    UBS
    More analyst ratings

    $BFLY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Butterfly Network to Participate in the William Blair 46th Annual Growth Stock Conference

    The Company presentation will occur at 8:40 AM CT on Thursday, June 4, 2026 Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), today announced that the company will participate at the William Blair 46th Annual Growth Stock Conference. Joseph DeVivo, President, Chief Executive Officer & Chairman and John Doherty, EVP, Chief Financial Officer will participate in a presentation breakout session at 8:40 AM CT on June 4, 2026, and host one-on-one investor meetings throughout the day. A webcast of the presentation will be available in the Events & Presentations section of the Butterfly investor website (https://ir.butterflynetwork.com/events-and-presentations). To schedule a one-on-one meet

    5/21/26 4:05:00 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts

    Issued on behalf of Ventripoint Diagnostics Ltd.A Toronto-based small-cap is converting clinical validation into real-world hospital deployments at the moment AI cardiac imaging procurement is reorganizing globallyNEW YORK, May 19, 2026 /CNW/ -- USA News Group News Commentary — Cardiology has become one of the proving grounds for medical artificial intelligence, and the procurement environment around it has shifted hard in the last twelve months. Hospital networks are no longer content to evaluate clinical accuracy in isolation; they want department-level economic proof before they sign deployment contracts. That shift is reshaping which AI imaging companies can convert pilot data into recur

    5/19/26 8:55:00 AM ET
    $BFLY
    $GEHC
    $RDNT
    Medical Electronics
    Health Care
    Medical Specialities
    Computer Software: Programming Data Processing

    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

    VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at

    5/13/26 9:00:00 AM ET
    $BFLY
    $CTKB
    $HTFL
    Medical Electronics
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BFLY
    SEC Filings

    View All

    Butterfly Network Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Butterfly Network, Inc. (0001804176) (Filer)

    5/8/26 8:07:20 AM ET
    $BFLY
    Medical Electronics
    Health Care

    SEC Form 10-Q filed by Butterfly Network Inc.

    10-Q - Butterfly Network, Inc. (0001804176) (Filer)

    4/30/26 7:33:32 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Butterfly Network, Inc. (0001804176) (Filer)

    4/30/26 7:01:43 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Butterfly Network downgraded by Oppenheimer

    Oppenheimer downgraded Butterfly Network from Outperform to Perform

    8/1/25 12:44:19 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Craig Hallum initiated coverage on Butterfly Network with a new price target

    Craig Hallum initiated coverage of Butterfly Network with a rating of Buy and set a new price target of $3.00

    7/1/25 8:24:04 AM ET
    $BFLY
    Medical Electronics
    Health Care

    William Blair initiated coverage on Butterfly Network

    William Blair initiated coverage of Butterfly Network with a rating of Outperform

    3/17/25 7:23:53 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Neubauer Caroll H was granted 73,170 shares (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    5/21/26 4:10:27 PM ET
    $BFLY
    Medical Electronics
    Health Care

    SEC Form 3 filed by new insider Neubauer Caroll H

    3 - Butterfly Network, Inc. (0001804176) (Issuer)

    5/21/26 4:09:38 PM ET
    $BFLY
    Medical Electronics
    Health Care

    CAO and SVP, Finance Carlson Megan sold $524,394 worth of shares (110,422 units at $4.75), decreasing direct ownership by 18% to 507,209 units (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    5/5/26 4:05:29 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Phanstiel S. Louise bought $571,160 worth of shares (185,261 units at $3.08) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/17/25 4:10:13 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $64,471 worth of shares (21,370 units at $3.02) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/15/25 6:20:36 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Robbins Larry bought $4,652,773 worth of shares (1,558,541 units at $2.99) (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    12/5/25 5:40:49 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Leadership Updates

    Live Leadership Updates

    View All

    A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech

    VMS+™ 4.0 system collects a 2026 Edison Award Gold Medal, advances to NMPA regulatory submission in China, and heads to the AEPC pediatric cardiology meeting in Padua, Italy VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — The AI-cardiac-diagnostics category is one of the more measurable inflection points in the broader medtech sector heading into the second half of 2026. The global AI cardiology market is projected to reach approximately US$2.78 billion in 2026 and climb past US$14 billion by 2034 as software-based diagnostics replace hardware-based imaging across an aging patient base and a healthcare system increasingly cost-pressured at

    5/13/26 9:00:00 AM ET
    $BFLY
    $CTKB
    $HTFL
    Medical Electronics
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Butterfly Network Appoints Caroll H. Neubauer to Board of Directors

    Seasoned Medtech Leader and Former Chairman and CEO of B. Braun of America Brings Deep Healthcare Industry Expertise Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of Caroll H. Neubauer to its Board of Directors, effective May 18, 2026. Mr. Neubauer will serve on the Board's Compensation Committee and Technology Committee. Mr. Neubauer has achieved a distinguished career spanning three decades with B. Braun, including serving for 29 years on the Global Management Board of the B. Braun Group of Companies. During his tenure, he helped grow annual revenue

    5/8/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network Appoints Arun Nagdev, MD as Chief Medical Officer – POCUS

    Prominent POCUS thought leader joins to advance clinical strategy and further Butterfly's mission to democratize ultrasound worldwide. Butterfly Network (NYSE:BFLY), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of Arun Nagdev, MD as Chief Medical Officer – Point-of-Care Ultrasound (POCUS). In this role, Dr. Nagdev will lead the global medical strategy for the Company's core POCUS business, advancing clinical product validation, strengthening customer engagement, and supporting regulatory and clinical development efforts. Dr. Nagdev brings more than 20 years of experience advancing POCUS adoption, educ

    4/21/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

    SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

    9/3/24 7:10:06 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

    SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

    8/30/24 4:05:41 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by Butterfly Network Inc.

    SC 13G/A - Butterfly Network, Inc. (0001804176) (Subject)

    7/8/24 4:32:42 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    Financials

    Live finance-specific insights

    View All

    Butterfly Network Reports First Quarter 2026 Financial Results

    Delivered Revenue Above Consensus and Beat Adjusted EBITDA Guidance Reaffirmed full year Revenue and Adjusted EBITDA Guidance Delivered quarterly Revenue of $26.5 million in Q1, representing 25% YoY growth Delivered 69% Gross Margin up 600 bps and Adjusted EBITDA of ($6.1M) up 32% YoY Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. Joseph DeVivo, Butterfly's President, Chief Executive Officer and Chairman commented, "Butterfly opened the year with ano

    4/30/26 6:30:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network to Report First Quarter 2026 Financial Results on April 30, 2026

    Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, announced that it will report first quarter 2026 financial results on Thursday, April 30, 2026, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer, will host a conference call and webcast before the market opens on April 30 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations website at Events & Presentations.

    4/16/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Butterfly Network Reports Fourth Quarter 2025 Financial Results

    Delivered Record Annual and Quarterly Revenue Reported quarterly record Revenue of $31.5 million in Q4, representing 41% YoY growth Generated positive net cash flow of $6.3 million in Q4 and lowest annual cash usage in company history Midjourney partnership contributed $6.8 million of revenue in Q4, advancing Butterfly Embedded™ platform strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Joseph DeVivo, Butterfly's Presiden

    2/26/26 6:30:00 AM ET
    $BFLY
    Medical Electronics
    Health Care